RELATIONSHIP BETWEEN RPOB MUTATIONS AND MINIMUM INHIBITORY CONCENTRATIONS OF RIFAMPICIN IN MULTI DRUG RESISTANT STRAINS OF MYCOBACTERIUM TUBERCULOSIS

Authors

  • Shashikant Vaidya Department of Clinical Pathology, Haffkine Institute for Training, Research and Testing, Mumbai, India
  • Jinesh Maniar Department of Clinical Pathology, Haffkine Institute for Training, Research and Testing, Mumbai, India
  • Shreyasi Muley Hafting Bio-pharmaceutical Corporation Ltd. Mumbai, India
  • Geeta Koppikar Breach Candy HospitalTrust, Mumbai, India
  • Mohan Kulkarni T.N. Medical College and B.Y.L. Nair Charitable Hospital, Mumbai, India
  • Abhay Chowdhary Grant Government Medical College and Sir J.J. Hospital, Mumbai, India

DOI:

https://doi.org/10.20319/lijshls.2015.s11.108121

Keywords:

ROPB, Rifampicin, Multi Drug Resistancem, Tuberculosis

Abstract

Tuberculosis is an infectious disease caused by obligate intracellular bacteria Mycobacterium tuberculosis, which has created a health problem worldwide. Incidence of Multi-drug resistance tuberculosis creates the scenario dangerous, which is resistant to both the first line drugs namely Rifampicin and ionized. Mutation in rpoB and inhA confers resistance to rifampicin and ionized respectively. In the present study we studied the relationship between rpoB mutations and minimum inhibitory concentrations of Rifampicin in Multi drug resistant(MDR) strains of Mycobacterium tuberculosis. Total 20 MDR strains were selected for the study. The mutations in the rpoB gene were identified by sequencing the PCR products. The minimum inhibitory concentrations of Rifampicin, was determined by Absolute Concentration method. Mutations conferring resistance to Rifampicin in Mycobacterium tuberculosis occurs in the defined region of 81 base pair of rpoB gene. The most frequent mutation found in Rifampicin resistant strain is at position 532, 526 and 516. Mutation occurring at this position results in high level of Rifampicin resistance. Mutation at 511, 518 and 522 is associated with low level of Rifampicin resistance. 

References

Ahmad, S., Araj, G. F., Akbar, P. K., Fares, E., Chugh, T. D., & Mustafa, A. S. (2000). Characterization of rpoB mutations in rifampin-resistant Mycobacterium tuberculosis isolates from the Middle East. Diagnostic microbiology and infectious disease, 38(4), 227-232.

Hacek, A., Brzostek, A., Augustynowicz-Kopec, E., Zwolska, Z. andDiadem, J. (2009).Genetic evaluation of relationship between mutations inrpoB and resistance of Mycobacterium tuberculosis torifampin. BMC Microbiology 2009, 9:10doi:10.1186/1471-2180-9-10

Bodmer, T., Zürcher, G., Imboden, P., & Telenti, A. (1995). Mutation position and type of substitution in the β-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis. Journal of Antimicrobial Chemotherapy, 35(2), 345-348.

Canetti, G., Froman, S., Grosset, J. a., Hauduroy, P., Langerova, M., Mahler, H., Šula, L. (1963). Mycobacteria: laboratory methods for testing drug sensitivity and resistance. Bulletin of the World Health Organization, 29(5), 565.

Cornwall, J. (1997). Tuberculosis: a clinical problem of international importance. The Lancet, 350(9078), 660-661.

Genei. (2005). Genei Quick PCR purification kit manual (pp. Catalog no. K2 65).

Heep, M., Brandstätter, B., Rieger, U., Lehn, N., Richter, E., Rüsch-Gerdes, S., & Niemann, S. (2001). Frequency of rpoB mutations inside and outside the cluster I region in rifampinresistant clinical Mycobacterium tuberculosis isolates. Journal of clinical microbiology, 39(1), 107-110.

Jenkins, C., Claxton, A. P., Shorten, R. J., McHugh, T. D., & Gillespie, S. H. (2005). Rifampicin resistance in tuberculosis outbreak, London, England. Emerg Infect Dis, 11(6), 931-934.

Jamieson, F. B., Guthrie, L., Neemuchwala,A.,Lastovetska, O.,Melano, R. G and Mehaffy,C. (2014).J ClinMicrobiol. 2014 Jun; 52(6): 2157–2162.

Kawa, D. E., Pennell, D., Kubista, L., & Schell, R. (1989). Development of a rapid method for determining the susceptibility of Mycobacterium tuberculosis to isoniazid using the Gen- Probe DNA Hybridization System. Antimicrobial agents and chemotherapy, 33(7), 1000- 1005.

Mani, C., Selvakumar, N., Narayanan, S., & Narayanan, P. (2001). Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis clinical isolates from India. Journal of clinical microbiology, 39(8), 2987-2990.

Mitchison, D. (1974). Bacteriology of tuberculosis. Tropical doctor, 4(4), 147.

Mitchison, D. (2005). Drug resistance in tuberculosis. European Respiratory Journal, 25(2), 376-379.

Pozzi, G., Meloni, M., Iona, E., Orru, G., Thoresen, O., Ricci, M., Orefici, G. (1999). rpoB mutations in multidrug-resistant strains of Mycobacterium tuberculosis isolated in Italy. Journal of Clinical Microbiology, 37(4), 1197-1199.

Ramaswamy, S., & Musser, J. M. (1998). Molecular genetic basis of antimicrobial agent resistance inMycobacterium tuberculosis: 1998 update. Tubercle and Lung Disease, 79(1), 3-29.

Rosha, D., & Kataria, V. (2001). Impact of initial drug resistance pattern on the maintenance phase of short course chemotherapy with reference to the emergence of multi drug resistance. Indian Journal Of Tuberculosis, 48(4), 205-208.

Schilke, K., Weyer, K., Bretzel, G., Amthor, B., Brandt, J., Sticht-Groh, V., . . . Haas, W. (1999). Universal pattern of rpoB gene mutations among multidrug-resistant isolates of Mycobacterium tuberculosis complex from Africa. The International Journal of Tuberculosis and Lung Disease, 3(7), 620-626.

Siddiqi, N., Shamim, M., Jain, N., Rattan, A., Amin, A., Katoch, V., Hasnain, S. E. (1998). Molecular genetic analysis of multi-drug resistance in Indian isolates of Mycobacterium tuberculosis. Memórias do Instituto Oswaldo Cruz, 93(5), 589-594.

Siddiqui, S. H., Libonati, J.P. and Middlebrook, G. (1981). Evaluation of a rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol, 13, 908-912.

Telenti, A., Imboden, P., Marchesi, F., Matter, L., Schopfer, K., Bodmer, T., Cole, S. (1993). Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. The Lancet, 341(8846), 647-651.

Valim, A. R. M., Rossetti, M. L. R., Ribeiro, M. O., & Zaha, A. (2000). Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis isolates from Brazil. Journal of Clinical Microbiology, 38(8), 3119-3122.

Van-Embden, J., Cave, M. D., Crawford, J. T., Dale, J., Eisenach, K., Gicquel, B., . Shinnick, T. (1993). Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. Journal of clinical microbiology, 31(2), 406-409.

Downloads

Published

2015-07-01

How to Cite

Vaidya, S., Maniar, J., Muley, S., Koppikar, G., Kulkarni, M., & Chowdhary, A. (2015). RELATIONSHIP BETWEEN RPOB MUTATIONS AND MINIMUM INHIBITORY CONCENTRATIONS OF RIFAMPICIN IN MULTI DRUG RESISTANT STRAINS OF MYCOBACTERIUM TUBERCULOSIS. LIFE: International Journal of Health and Life-Sciences, 1(01), 108–121. https://doi.org/10.20319/lijshls.2015.s11.108121

Most read articles by the same author(s)